{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04232592",
      "OrgStudyIdInfo": {
        "OrgStudyId": "Chinese ASZQ-005"
      },
      "Organization": {
        "OrgFullName": "Chinese Academy of Sciences",
        "OrgClass": "OTHER_GOV"
      },
      "BriefTitle": "Clinical Safety Study of Human Embryonic Stem Cell Derived Mesenchymal Cells in the Treatment of Moderate and Severe Intrauterine Adhesions",
      "OfficialTitle": "Clinical Safety Study of Human Embryonic Stem Cell Derived Mesenchymal Cells in the Treatment of Moderate and Severe Intrauterine Adhesions"
    },
    "StatusModule": {
      "StatusVerifiedDate": "December 2019",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Not yet recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "January 2020",
        "StartDateType": "Anticipated"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "January 2022",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "January 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "December 27, 2019",
      "StudyFirstSubmitQCDate": "January 15, 2020",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "January 18, 2020",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "January 15, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "January 18, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor-Investigator",
        "ResponsiblePartyInvestigatorFullName": "Qi Zhou",
        "ResponsiblePartyInvestigatorTitle": "Director of Institute of zoology, chinese academy of sciences, and vice president of medical school， University of chinese academy of sciences",
        "ResponsiblePartyInvestigatorAffiliation": "Chinese Academy of Sciences"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Qi Zhou",
        "LeadSponsorClass": "OTHER_GOV"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Tongji Hospital",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "To observe the clinical safety of intrauterine injection of human embryonic stem cell derived mesenchymal cells in the treatment of moderate and severe intrauterine adhesion, and to preliminarily explore its clinical effectiveness in promoting endometrial regeneration and repair.",
      "DetailedDescription": "In this study, a single-center, controlled, open-label design was used for a dose escalation study.To observe the clinical safety of intrauterine injection of human embryonic stem cell derived mesenchymal cells in the treatment of moderate and severe intrauterine adhesion, and to preliminarily explore its clinical effectiveness in promoting endometrial regeneration and repair."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Intrauterine Adhesion"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "32",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Stem cell preparation solution injection group",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "The solution of stem cells preparation will be injected.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Inject a solution of stem cell preparation"
              ]
            }
          },
          {
            "ArmGroupLabel": "Injected stem cell group",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "The stem cells will injected.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Inject stem cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Inject a solution of stem cell preparation",
            "InterventionDescription": "The control group was injected with a solution of stem cell preparation",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Stem cell preparation solution injection group"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "Inject stem cells",
            "InterventionDescription": "Three dose groups were designed: low dose group, medium dose group and high dose group.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Injected stem cell group"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Incidence of different Adverse Events of transplantation of mesenchymal cells from human embryonic stem cells",
            "PrimaryOutcomeDescription": "Adverse events (AE), severe adverse events (SAE), and treatment-related adverse events (TEAE) occurred within 48 weeks after surgery.",
            "PrimaryOutcomeTimeFrame": "Within 48 weeks after surgery"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Normal recovery rate of endometrial thickness",
            "SecondaryOutcomeDescription": "Normal recovery rate of endometrial thickness at 1 and 2 months after surgery will be measured (effective rate = endometrium > 6mm after surgery/all participants ×100%).",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "recurrence rate of intrauterine adhesions",
            "SecondaryOutcomeDescription": "Recurrence rate of intrauterine adhesions (defined as patients with recurrence of intrauterine adhesions reviewed by hysteroscopy at 1 month/total patients ×100%) will be measured.",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Intrauterine adhesions score",
            "SecondaryOutcomeDescription": "Intrauterine adhesions score will be measured according to the American Fertility Society in 1988 diagnostic criteria for intrauterine adhesions.The scores range from 1 to 12. Higher scores mean a worse outcome.",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "The endometrial biopsies for CD31",
            "SecondaryOutcomeDescription": "Immunohistochemical results of CD31 during the two endometrial biopsies will be measured.",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Menstrual volume change",
            "SecondaryOutcomeDescription": "Menstrual volume change will be assessed according to menstrual blood loss chart.",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Clinical pregnancy rate",
            "SecondaryOutcomeDescription": "Clinical pregnancy rate, abortion rate, live birth rate, and sustained pregnancy rate (defined as live pregnancy over 12 weeks) will be assessed.",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "The endometrial biopsies for estrogen",
            "SecondaryOutcomeDescription": "Estrogen receptor levels during the two endometrial biopsies will be measured.",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "The endometrial biopsies for Ki67",
            "SecondaryOutcomeDescription": "Ki67 expression levels during the two endometrial biopsies will be measured.",
            "SecondaryOutcomeTimeFrame": "12 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Criteria:\n\nInclusion Criteria:\n\n18 ≤ age ≤38, female;\nAccording to the 1988 American Fertility Society (AFS) diagnostic criteria, patients with uterine adhesions diagnosed with full civil capacity and with a score of ≥5 were enrolled in the study;\nThe patient had one or more of the following clinical symptoms: reduced menstruation or amenorrhea, periodic abdominal pain, secondary infertility, recurrent abortion, premature delivery and other adverse pregnancy outcomes;\nThe uterus was smaller than 8 weeks gestation and the uterine cavity depth was less than 12 cm;\nThe second to fifth day of menstruation FSH <10mIU/mL, AMH >1.2ng/mL, AFC>6;\nUnderstand and sign informed consent voluntarily.\n\nExclusion Criteria:\n\nPatients with acute pelvic inflammation or endometriosis;\nHaving or having a history of malignancy;\nThrombus, lupus erythematosus and other hormone use contraindications; Allergic to albumin products;\nPatients with uterine malformation, adenomyosis, submucosal uterine fibroids,and uterine fibroids of any site >5cm;\nPatients who were using anticoagulants or who had not recovered normal platelet function 10 days after discontinuation of antiplatelet drugs;\nPrevious history of abnormal coagulation function or abnormality before cell transplantation;\nAlways has a history of abnormal bleeding (such as abnormal bleeding during tooth extraction), or their immediate family members have hemorrhagic disease,such as hemophilia, bleeding symptoms (e.g., hematemesis, black, serious or recurrent nasal bleeding, coughing up blood, obvious hematuria, gastrointestinal bleeding, or intracranial hemorrhage), or suspected of vascular malformation such as aneurysm by researchers determine influence cell implant operation;\nAlcohol or drug addiction;\nParticipated in other interventional clinical trials within 90 days before the informed consent was signed or before the cell transplantation;\nHad used glucocorticoids or immunosuppressive drugs within 12 weeks before signing the informed consent;\nHad used antipsychotic drugs, such as antidepressants and anti-manic drugs, within 12 weeks before signing the informed consent;\nSevere heart failure within 24 weeks before the informed consent;\nGlomerular filtration rate (eGFR) <90ml/min;\nALT>3 times normal upper limit;\nConcomitant with other serious systemic diseases, such as pulmonary heart disease, severe chronic obstructive pulmonary disease (COPD), etc;\nPatients with severe clinical infection should receive antibiotics within 1 week before signing the informed consent;\nActive infectious diseases, including but not limited to positive human immunodeficiency virus and syphilis antibody;\nThe researchers considered poor compliance;\nOther conditions not suitable for participation in this clinical trial.",
      "HealthyVolunteers": "No",
      "Gender": "Female",
      "GenderBased": "Yes",
      "MinimumAge": "18 Years",
      "MaximumAge": "38 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Liu Wang, Doctor",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+86-01064807858",
            "CentralContactEMail": "wangliu@ioz.ac.cn"
          },
          {
            "CentralContactName": "Jie Hao, Doctor",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+86-01062558737",
            "CentralContactEMail": "haojie@ioz.ac.cn"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Qi Zhou, Doctor",
            "OverallOfficialAffiliation": "Institute of zoology, Chinese Academy of Sciences",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000000267",
            "ConditionMeshTerm": "Tissue Adhesions"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000002921",
            "ConditionAncestorTerm": "Cicatrix"
          },
          {
            "ConditionAncestorId": "D000005355",
            "ConditionAncestorTerm": "Fibrosis"
          },
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M2772",
            "ConditionBrowseLeafName": "Tissue Adhesions",
            "ConditionBrowseLeafAsFound": "Adhesion",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M5312",
            "ConditionBrowseLeafName": "Cicatrix",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M7637",
            "ConditionBrowseLeafName": "Fibrosis",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M21013",
            "InterventionBrowseLeafName": "Pharmaceutical Solutions",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "PhSol",
            "InterventionBrowseBranchName": "Pharmaceutical Solutions"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}